Piclidenoson - Can-Fite Biopharma

Drug Profile

Piclidenoson - Can-Fite Biopharma

Alternative Names: CF-101; IB-MECA; SI-615

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Can-Fite BioPharma
  • Class Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Apoptosis inhibitors; Immunosuppressants; Interleukin 17 receptor antagonists; Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II/III Plaque psoriasis
  • Phase II Glaucoma
  • Phase I Uveitis
  • Preclinical Osteoarthritis
  • Discontinued Colorectal cancer; Dry eyes; Solid tumours

Most Recent Events

  • 30 Jan 2018 Can-Fite BioPharma withdraws a phase II trial prior to enrolment for Osteoarthritis in Israel as the company has decided not to conduct the study (PO) (NCT00837291)
  • 30 Jan 2018 Can-Fite BioPharma withdraws a phase II trial prior to enrolment as the company decided not to conduct the study for Uveitis in Israel (PO) (NCT01905124)
  • 08 Jan 2018 Can-Fite Biopharma and Gebro Pharma enters into an exclusive distribution agreement for piclidenoson for Psoriasis and Rheumatoid arthritis in Austria, Spain and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top